2022 is witnessing a sharp drop in global biotech investments by venture capital funds.
Data compiled by Wisdomsmith shows venture capital funds invested $15.8B in biotech and healthcare sector over Jan-Apr’22, as compared to $27B over the same period in 2021. That’s a drop of 41%.
While the drop is fairly universal, China has seen the biggest drop, investments in China are down 71% on a yoy basis.
Correction in public markets, and lack of appetite for biotech IPOs is given as the key reason for the sharp pullback in the private space as well. 2021 was a record year, given the prevailing world focus on health.